Obsessive-compulsive Disorder
📧 Sign up to get email alerts when something new happens for Obsessive-compulsive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-08-27FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for a fluoxetine hydrochloride generic product from PAI Holdings (PAI Pharma). This action approves …
-
FDA approval · 2021-08-27FDA Approved: PAROXETINE — Original Application (Modavar Pharmaceuticals LLC)
FDA approved a generic paroxetine tablet product from Modavar Pharmaceuticals LLC under an original abbreviated new drug application (ANDA 2…
-
FDA approval · 2021-08-25FDA Approved: FLUOXETINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
The FDA approved a supplemental application for Fluoxetine from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2021-08-23FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Supplemental Application (Northstar Rx LLC.)
FDA approved a supplemental application for clomipramine hydrochloride from Northstar Rx LLC., enabling the generic product's continued regu…
-
CLINICAL_TRIALS trial_result · 2021-08-20Clinical Trial Update: Memantine for Refractory OCD Patients [Phase 3]
Phase 3 clinical trial investigating memantine for refractory obsessive-compulsive disorder is reported as ongoing with unknown status.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-08-04FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Inc.)
The FDA approved Alembic Pharmaceuticals' generic clomipramine hydrochloride through an original ANDA.
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder [Phase 4]
A Phase 4 clinical trial exploring sertraline combined with fluvoxamine for refractory obsessive-compulsive disorder.
-
CLINICAL_TRIALS trial_result · 2021-05-14Clinical Trial Update: Rapid Non-Invasive Brain Stimulation for OCD (oTMS) [NA]
A completed clinical trial evaluating rapid non-invasive brain stimulation for obsessive-compulsive disorder (oTMS) with results posted in 2…
-
FDA approval · 2021-05-03FDA Approved: SERTRALINE HYDROCHLORIDE — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved the original application for sertraline hydrochloride generic by XLCare Pharmaceuticals, enabling a generic version to be marke…
-
CLINICAL_TRIALS trial_result · 2021-04-27Clinical Trial Update: Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. [Phase 4]
Phase 4 clinical trial update evaluating fear-conditioned responses in healthy subjects and OCD patients before and after sertraline treatme…
-
FDA approval · 2021-04-19FDA Approved: FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for fluoxetine from Teva Pharmaceuticals USA, Inc., updating the generic's labeling under the AN…
-
FDA approval · 2021-02-16FDA Approved: PAROXETINE — Original Application (Westminster Pharmaceuticals, LLC)
The FDA approved Westminster Pharmaceuticals' generic paroxetine (PAROXETINE) via an Original Application (ANDA213485). It covers indication…
-
CLINICAL_TRIALS trial_result · 2021-02-11Clinical Trial Update: Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? [Phase 4]
Phase 4 trial evaluating whether D-cycloserine can enhance and stabilize treatment response in relapsed and non-responding patients with obs…
-
FDA approval · 2021-02-06FDA Approved: PAXIL — Supplemental Application (Apotex Corp)
FDA approved a supplemental application for Paxil (paroxetine hydrochloride) submitted by Apotex Corp.
-
FDA approval · 2021-01-21FDA Approved: FLUOXETINE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine submitted by Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2021-01-05Clinical Trial Update: Effects of Sertraline on Brain Connectivity in Adolescents With OCD [Phase 1, Phase 2]
A completed trial evaluating the effects of sertraline on brain connectivity in adolescents with obsessive-compulsive disorder, with results…
-
FDA approval · 2020-12-23FDA Approved: FLUOXETINE — Supplemental Application (Cadila Pharmaceuticals Limited)
FDA approved a supplemental application for Fluoxetine from Cadila Pharmaceuticals Limited, enabling the marketing of this generic fluoxetin…
-
FDA approval · 2020-12-17FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Apotex Corp)
The FDA approved a supplemental application for fluvoxamine maleate from Apotex Corp, resulting in approval of a generic version.
-
FDA approval · 2020-11-13FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for fluvoxamine maleate from Actavis Pharma, Inc. under an ANDA.
-
CLINICAL_TRIALS trial_result · 2020-09-29Clinical Trial Update: The Modular Protocol for Mental Health (MPMH) [Phase 1, Phase 2]
Phase 1 and Phase 2 study of the Modular Protocol for Mental Health (MPMH) completed; investigates treatment approaches for multiple mental …
-
CLINICAL_TRIALS trial_result · 2020-09-01Clinical Trial Update: Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD) [Phase 4]
Phase 4 trial evaluating the efficacy of adding topiramate to current treatment in refractory obsessive-compulsive disorder.
-
CLINICAL_TRIALS trial_result · 2020-08-27Clinical Trial Update: The Use of Magnetic Brain Stimulation to Treat Obsessive Compulsive Disorder, a Pilot Study [NA]
Pilot study evaluating magnetic brain stimulation as a treatment for obsessive-compulsive disorder; trial completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-17Clinical Trial Update: Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD) [Phase 1, Phase 2]
Clinical trial update on ketamine for pediatric-refractory obsessive-compulsive disorder with completed Phase 1 and Phase 2, results posted …
-
FDA approval · 2020-08-07FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved the original application for clomipramine hydrochloride (generic) from Rising Pharma Holdings, Inc., enabling a generic product…
-
FDA approval · 2020-07-21FDA Approved: PAROXETINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for Paroxetine hydrochloride from Apotex Corp., enabling continued marketing of a generic product.